Form 4: CytomX Therapeutics Director Alan Ashworth Granted 38,000 Stock Options

CytomX Therapeutics, Inc. director Alan Ashworth was granted 38,000 stock options with an exercise price of $2.82, aligning his interests with shareholder value.

Summary

• Alan Ashworth, a Director of CytomX Therapeutics, Inc. (CTMX), was granted 38,000 stock options.
• The options have an exercise price of $2.82 per share.
• The grant date for these options was June 11, 2025.
• The options are exercisable as to 100% of the total shares on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the 2026 Annual Meeting of Stockholders, contingent on continuous service.
• The options expire on June 10, 2035.

Sentiment

Score: 6

Explanation: Slightly positive as it represents routine director compensation aligning interests, with no negative financial implications reported.

Positives

• The grant of stock options to Director Alan Ashworth aligns his financial interests with the long-term performance of CytomX Therapeutics, Inc.
• Equity compensation is a standard practice to incentivize directors and retain talent.

Risks

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity.

Future Outlook

The vesting schedule of the options incentivizes Director Ashworth's continued service and contribution to the company's performance until at least the first anniversary of the grant date or the 2026 Annual Meeting.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries to attract and retain experienced board members and align their interests with long-term company success and shareholder value creation.

Related Party Transactions

• The grant of 38,000 stock options to Director Alan Ashworth by CytomX Therapeutics, Inc. constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from increased alignment of director's interests with company performance.

Next Steps

• Vesting of the 38,000 stock options on the earlier of June 11, 2026, or the 2026 Annual Meeting of Stockholders.
• Potential future exercise of the options by Alan Ashworth.

Key Dates

Recommendation

Keywords

CytomX Therapeutics, CTMX, Stock Option, Director Compensation, Insider Transaction, Form 4, Equity Grant, Alan Ashworth, Biotechnology, Pharmaceutical